Methadone
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Methadone: From Opioid Dependence and Pain Treatment to Tourette Syndrome
One-Sentence Summary
Methadone is a long-acting opioid agonist, generally used for opioid dependence and severe pain. The TxGNN model predicts it may be effective for Tourette syndrome, but there are 0 registered clinical trials and only 1 small clinical report (1992) directly on this use. Overall this is a hypothesis-generating prediction with very limited evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the supplied label data (methadone is generally used for opioid dependence and severe pain) |
| Predicted New Indication | Tourette syndrome |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five shown are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, methadone is a mu-opioid receptor agonist with established use in opioid dependence and pain. Mechanistically it may be applicable to Tourette syndrome, but this is not confirmed by the supplied data.
The most plausible route is opioid-system modulation of dopaminergic and striatal circuits, which are involved in tics. A 1992 report describes methadone treatment of Tourette’s disorder. A 2007 preclinical paper also notes that opioid drugs are effective in treatment-refractory OCD and Tourette syndrome, and links a 5-HT2A-related behavior to tics.
The rest of the retrieved literature is indirect. It covers heroin addiction in Tourette patients, chorea reviews and pain reviews. There are no controlled data, so the model score is not backed by clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1728167 | 1992 | Case report / small clinical series | Am J Psychiatry | “Methadone treatment of Tourette’s disorder.” The only direct clinical report. No abstract was available, and it is old and uncontrolled. |
| 30395551 | 2018 | Observational / case series | J Psychiatr Pract | Heroin addiction in Serbian patients with Tourette syndrome. It shows comorbidity with addiction, not treatment benefit. |
| 17102981 | 2007 | Preclinical (indirect) | Psychopharmacology | Atypical opiates in OCD, studied through 5-HT2A/C receptor-mediated behavior. It notes that opiates are also effective in refractory OCD and Tourette syndrome. |
| 15247538 | 2004 | Review (indirect) | Curr Opin Neurol | Review of non-genetic causes of chorea. It is only loosely related to Tourette syndrome. |
| 39086469 | 2024 | Review (not relevant) | Palliat Care Soc Pract | Novel drugs for neuropathic pain in advanced cancer. It does not address Tourette syndrome. |
US Market Information
The supplied records do not include approved indication text. Five of the 20 licenses are shown below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA212093 | Methadone Hydrocloride | Concentrate | Atlantic Biologicals Corp. |
| ANDA203502 | Methadone Hydrochloride | Tablet | Aurolife Pharma, LLC |
| ANDA212093 | Methadone Hydrocloride | Concentrate | Bryant Ranch Prepack |
| ANDA077142 | Methadone Hydrochloride | Tablet | SpecGx LLC |
| ANDA074184 | Methadose Dispersible | Tablet | SpecGx LLC |
Dosage forms on the US market include oral tablets, concentrate, solution and injection.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only direct support for methadone in Tourette syndrome is a single 1992 clinical report, with no registered trials and no controlled data. The high model score (99.76%) is not corroborated, so this stays a research question.
To proceed, the following is needed:
- Mechanism of action data for methadone, to test the proposed opioid–dopaminergic link
- The US package insert (warnings and contraindications), which is needed for any safety screening
- A systematic literature review, including a search for later case series or trials in Tourette syndrome
- A risk–benefit assessment against established Tourette therapies, given methadone’s dependence and safety profile
- Consideration of the other predicted indications in the same pack. Headache disorder has slightly more evidence (a 2021 prospective study of low-dose methadone in refractory chronic migraine), but it carries conflicting signals, including opioid-induced hyperalgesia and medication-overuse headache.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.